NORMAL IMMUNOGLOBULIN, HUMAN

Concentrated antibodies recovered from pooled human plasma or serum; contains immunoglobulin G and antibodies to hepatitis A, measles, mumps, rubella, varicella or other prevalent viruses

Dosage Forms

▼

Solution for Injection

16%

Uses

▼
  • Protection of exposed patients against hepatitis A, measles and rubella

Dose and Duration

▼

Give as SC infusion; if SC is not possible, give IM injection except in patients with thrombocytopenia or bleeding disorders

Consult manufacturer’s literature for doses

Contraindications

▼
  • Hypersensitivity to any of the components
  • IV administration

Side Effects

▼
  • Anxiety
  • Dizziness, migraine, tingling or pricking sensation, headache, fatigue, increased sweating
  • Flushing, increase in blood pressure, thromboembolic events such as myocardial infarction, stroke, pulmonary embolism and deep vein thrombosis, low blood pressure
  • Wheezing/asthma
  • Diarrhoea, mouth ulcer, abdominal pain, vomiting, nausea
  • Pruritus, rash, allergic reactions
  • Musculoskeletal pain/ stiffness
  • Chills, fever
  • Joint pain, moderate low back pain
  • Infusion site reactions (swelling, pain, redness, itching)

Interactions

▼
  • Live vaccine (impairment of immune response)

Pregnancy

▼
  • Can be used

Breast-feeding

▼
  • Can be used

Storage

▼
  • Store at 2–8 °C in the dark. Do not freeze

⚠️ Caution

▼
  • Risk of shock if injection is given intravenously
  • Formulations from different manufacturers vary and should not be treated as equivalent
  • Avoid use of live vaccine (except yellow fever vaccine) during 3 weeks before or during 3 months after injection of human normal immunoglobulin
  • In exposure to hepatitis A, immunoglobulin should be given within 14 days of exposure to a primary case, though can still be given up to 28 days.
  • In case of exposure to measles in immune compromised individuals, give immunoglobulin immediately within 72 hours of exposure. Can still be given within 6 days
  • If hepatitis A vaccine is given at the same time, it should be injected at a different site
  • Use with caution in patients with hypo- or agammaglobulinaemia with or without IgA deficiency
  • Monitor for acute renal failure and consider discontinuation if renal function deteriorates.
  • Always refer to the product information literature